Eli Lilly and Avidity Biosciences announce licensing & research cooperation
on combined monoclonal antibodies and oligonucleotide-based therapies for potential new medicines in immunology and other select indications.
Read more here: https://investor.lilly.com/news-releases/news-release-details/lilly-and-avidity-biosciences-announce-licensing-and-research